SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active ...

Researchers at Massachusetts Eye and Ear developed a preclinical research proof of concept that shows mRNA-based therapies ...

I’ve been eagerly anticipating a Medik8 Black Friday sale and, thankfully, my wish has been granted – there are indeed some ...

A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...

Campus Chemical Instrument Center, Mass Spectrometry & Proteomics Facility, The Ohio State University, Columbus, USA ...

A new study found that a novel mRNA-based therapy that targets a protein called RUNX1 may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR), a disease caused by a ...